The BMJ Today: High hopes—legal highs and pharmaceutical hype

The BMJ’s readers are used to maintaining scepticism in the face of hype and hyperbole, and two new articles suggest that this is a healthy position to maintain. Rory Watson reports on the growing number of new psychoactive substances, or “legal highs,” recognised by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). The number of […]

Read More…

K M Venkat Narayan: Global non-communicable diseases—the second in a series of reflections

On 30 April 2014, I wrote my first reflection on the topic of non-communicable diseases to whet your appetite, and promised seven more. My first reflection, if you recall, was: “Keep the growth of NCDs in perspective by acknowledging the incredible positive changes in life expectancy and economic wellbeing the world over—thanks to development and mechanization.” […]

Read More…

Jim Murray: Policy making behind closed doors

Campaigning for transparency on clinical trial results at EU level is getting to be like playing snakes and ladders, and I’ve just spotted three snakes. I’ve been trying to “deconstruct” the EMA’s reply by letter to the Ombudsman’s concerns about the agency’s volte-face on transparency. The results worry me—a lot. The EMA says that the […]

Read More…

Jane Feinmann: Is the current system of publishing clinical trials fit for purpose?

This question was the title of a meeting of the Medical Journalists’ Association last week, and, perhaps surprisingly for an audience made up almost exclusively of medical journalists, the response was a resounding no. So what happened? Medical journals, the main vehicles for publishing clinical trials today, are after all the “gatekeepers of medical evidence”—as they […]

Read More…